Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States
Ruben A. Mesa(Atrium Health Wake Forest Baptist), James K. Mangan(UC San Diego Health System), Maureen Thyne(Cornell University), John Mascarenhas(Tisch Hospital), Dilan Paranagama(Incyte (United States)), Ahmad Naim(Incyte (United States)), Salman Fazal(Allegheny Health Network), Sara Goldberger(Cancer Support Community), Carole B. Miller(Saint Agnes Hospital), Shreekant Parasuraman(Incyte (United States))
Cited by 5
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
|Journal of Clinical Oncology|2001|682
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
|Antimicrobial Agents and Chemotherapy|1993|344